FDA approves new cholesterol medication from Merck
The FDA has approved a new cholesterol-lowering pill developed by Merck. This medication offers an alternative to existing treatments. (sources: nbcnews, thehill, theguardian, foxnews, wsj)
The FDA has approved Lipfendra, a once-daily pill from Merck designed to significantly lower LDL cholesterol levels. The drug can be used alongside or instead of statins.
- Lipfendra is the first daily pill approved by the FDA specifically for lowering cholesterol levels.
- The medication can reduce LDL cholesterol by nearly 60%.
- It can be taken in conjunction with or as an alternative to statins.
Why it matters
This approval may provide patients with a new option for managing cholesterol levels.
↓ Congress can act on this
8 bills on this issue are moving right now — and the most active one is S3345: PBM Price Transparency and Accountability Act.
S3345 · 119th Congress
PBM Price Transparency and Accountability Act
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What S3345 actually does
This story is about FDA approves new kind of cholesterol pill. This bill would address abusive spread pricing in Medicaid and add Medicare PBM accountability and pharmacy-access rules.
If passed, it would:
- address abusive spread pricing in Medicaid and add Medicare PBM accountability and pharmacy-access rules • create a broader framework for PBM transparency and payment reform in federal drug programs.
7 other bills moving on this issue
Take action on any of them individually.
This story is about FDA approves new kind of cholesterol pill. This bill would require an exceptions process for medication step-therapy protocols in ERISA-governed coverage.
If passed, it would
- require an exceptions process for medication step-therapy protocols in ERISA-governed coverage • make it easier for prescribers to bypass inappropriate delays when a patient has already failed or cannot safely use.
This story is about FDA approves new kind of cholesterol pill. This bill would require health plans to count qualifying financial assistance toward patient cost-sharing obligations.
If passed, it would
- require health plans to count qualifying financial assistance toward patient cost-sharing obligations • reduce the risk that patients using assistance for a high-cost cholesterol drug still face a large deductible later in.
Sources used · 5 sources